Medscape
A new weight-loss compound targeting energy expenditure rather than appetite suppression showed early efficacy in a first-in-human study. The compound, SANA (MVD1; Eolo Pharma), activates creatine-dependent thermogenesis, a novel approach to obesity and metabolic disease compared to appetite suppression, explained Eolo Pharma CEO María Pía Garat…
Read More
Promising Weight-Loss Compound Targets Energy Expenditure
Lawanda Pekar
18:19
A new weight-loss compound targeting energy expenditure rather than appetite suppression showed early efficacy in a first-in-human study. The compound, SANA (MVD1; Eolo Pharma), activates creatine-dependent thermogenesis, a novel approach to obesity and metabolic disease compared to appetite suppression, explained Eolo Pharma CEO María Pía Garat…
